Introduction
Allergy remains one of the most common medical conditions, with significant clinical and economical relevance. Allergic diseases represent a highly variable, multifactorial group of disorders characterized by immune dysregulation and failure to develop tolerance towards innocuous environmental antigens. This underlying dysbalance has its roots as early as in the perinatal period. Prenatally, the foetus is maintained under Th2 bias to prevent unwanted reactivity towards antigenically foreign maternal determinants [1]. During the course of pregnancy, immunosuppressive environment supporting regulatory subpopulations is present in uterus under hormonal control [2]. Postnatally, new balance among the branches of immune system needs to be established – persisting Th2 predominance promotes sensitization and allergy development, while Th1 and Th17 branches play crucial roles in anti-infectious immunity but unchecked can cause autoimmune or inflammatory diseases [3].
Generally, neonatal immune system is immature. Proper development of immune responses together with setting tolerance to food antigens and compounds of microbiota is therefore necessary. This fine tuning of immunity in the early postnatal period is highly regulated and involves both intrinsic and extrinsic factors, chiefly exposure to microbial stimuli [4], consistent with the generally accepted hygiene hypothesis [5]. Intrinsically, regulatory T cells (Tregs) play a key role. This crucial immunomodulatory population of Th lymphocytes serves as master regulators capable of finely tuning balance among the other branches of immune response, maintaining peripheral tolerance and suppressing pathological immune reactions, including Th2-based allergy [3].
Human Tregs are commonly described as CD4+CD25high-CD127low population, further characterized by high dependence on IL-2, expression of lineage-specific transcription factor FoxP3 and demethylation of specific sequences within foxp3 promoter region (Treg-specific demethylated region – TSDR) [6, 7]. The functional relevance of these cells is evidenced by severe autoimmunity as well as allergy accompanying deficiency or impaired function of these cells [8, 9]. Tregs and their various subpopulations are thus indispensable for controlling allergic diseases both physiologically [3, 10] and in the context of specific allergen immunotherapy [11].
Regulatory T cells utilize numerous mechanisms for their suppressive and immunomodulatory functions, both contact-dependent (presence of cell surface molecules like e.g. CTLA-4, PD-1, LAG3, FasL) and remote (secretion of regulatory cytokines IL-10, TGF-b and IL-35) [12, 13]. Assessment of such Treg-associated markers is commonly used to indirectly assess functional capacity of Tregs, both on the level of individual cells (measured via flow cytometry, e.g. presence of surface or intracellular markers, median of fluorescence intensity [MFI] of FoxP3 [14]) and systemically (e.g. levels of regulatory cytokines in serum measured by ELISA [15, 16]).
Numerous subpopulations of Tregs were identified by flow cytometry, based upon differential expression of various surface and/or intracellular markers, as well as different biological functions. Gating strategies, sample preparation (particularly antibody clone selection), genetic background, clinical and environmental context and other factors can significantly influence Tregs, introducing discrepancies into published results. Therefore, it is vital to strive for consistency and to carefully consider the epidemiological and methodical aspects when interpreting studies published by different groups [17].
Despite marked progress in understanding the early processes involved in sensitization and allergy development, there is still lack of definite consensus regarding reliable early predictors of an individual’s increased risk of allergy. Numerous markers have been analysed in cord blood, including cord blood IgE levels [18], levels of cytokines including IL-10 and TGF-b in cord blood [15] and neonatal peripheral blood [19] plasma, as well as reactivity of cord blood cells to various stimuli, with limited conclusiveness when taken together [16, 20-23]. So far, the allergy status of the mother remains the strongest unambiguously accepted predictive factor [23].
Several studies have correlated population characteristics and functional properties of Tregs with atopic diseases in small infants [16, 24-27]. In our own work published by Hrdý in 2012 [17], we reported lower presence of intracellular markers associated with Treg function (IL-10, TGF-b, MFI of FoxP3) in Tregs from cord blood of children at higher risk of allergy development (based on maternal allergy status). Furthermore, we observed a slightly larger population of Tregs in cord blood of children of allergic mothers, possibly due to compensatory expansion of the population. We concluded by stating the importance of utilizing functional studies and above all the correlation of findings obtained from cord blood samples with the actual development of allergy in later life. In the current study, we perform retrospective analysis of a subset of data from the 2012 report, stratifying the previous findings according to the clinical allergy status of the children at the age of 6 to 10 years.
Material and methods
Subjects
The original study included a total of 153 healthy and allergic mothers with physiological pregnancies and children delivered vaginally at full term in the Institute for the Care of Mother and Child in Prague, Czech Republic [17]. The subjects were divided into two groups according to maternal allergic status, based on clinical manifestation of allergy persisting for over two years; monitoring by an allergist; positive skin prick tests and/or specific IgE antibodies; and anti-allergic treatment administered before pregnancy. The study including the current follow-up was approved by the Ethical Committee of the Institute for the Care of Mother and Child (Prague, Czech Republic) and carried out with the signed written informed consent of the mothers.
For the current follow-up study, the families originally included were contacted with a questionnaire in order to collect clinical data regarding manifestation of allergy in the children at the age of 6-10 years, confirmed by clinical examination by an allergist. A total of 39 responding subjects were included in the analysis, with the subjects subdivided into four groups based on combination of the allergy status of the mothers and the children themselves: allergic children of allergic mothers (A/A; n = 8), healthy children of allergic mothers (H/A; n = 12), allergic children of healthy mothers (A/H; n = 7) and healthy children of healthy mothers (H/H; n = 12).
Cord blood samples
Between 10 and 20 ml of umbilical cord blood were collected into sterile heparinised tubes for analysis of Treg population characteristics as well as intracellular presence of transcription factor FoxP3 and regulatory cytokines IL-10 and TGF-b by flow cytometry.
Flow cytometry
Whole blood samples were prepared and stained for flow cytometry analyses as described previously [17]. Briefly, samples of whole blood were stained for cell surface markers using the following antibodies: CD4-FITC, clone RPA-T4, cat. no. 555346; CD25- PE-Cy7, clone M-A251, cat. no. 557741; and CD127-Alexa 647, clone HIL-7R-M21, cat. no. 558598, all from Becton Dickinson (Franklin Lakes, NJ, USA). For intracellular staining, following antibodies were used: FoxP3-PE (clone PCH101, cat. no. 12-4776-41A; eBioscience, San Diego, CA, USA); IL-10-PE (clone JES3-19F1, cat. no. 506804) and TGF-b-PerCP-Cy5.5 (clone BG/hLAP, cat. no. 341803; both from BioLegend).
Proportion of Tregs and percentage of IL-10 and TGF-b positive Tregs were determined as described previously [17]. In the current study, data were re-analysed to obtain proportion of Tregs characterised as CD4+FoxP3+ using gating strategy shown in the Supplementary Figure 1. Briefly, lymphocytes were gated based on forward-scatter (FSC) and side-scatter (SSC) characteristics, followed by doublets exclusion based on FSC-A × FSC-H. CD4+ T cells were identified and Tregs then gated from this popu-lation as T cell subset positive for FoxP3.
Data acquisition and statistics
Flow cytometry data were acquired using BD FACSCanto II flow cytometer using BD FACS Diva version 6.1.2 software (Becton Dickinson) and analysed using FlowJo 7.2.2 (TreeStar. Ashland, OR, USA). Statistical and graphical analyses were performed using GraphPad Prism 6.0 (Graph Pad Software, La Jolla, CA, USA). Differences between the groups were compared using unpaired Student’s t-test in the case of normally distributed data (Treg ratios, MFI of FoxP3) and Mann-Whitney non-parametric test for the proportions of IL-10+ Tregs and TGF-b+ Tregs.
ELISA
Concentrations of regulatory cytokines IL-10 and TGF-b in the sera of cord blood were quantified by an enzyme-linked immunosorbent assay (ELISA) as described previously [15]. Briefly, primary (MAB 240) and secondary biotinylated (BAF 240) antibodies and recombinant protein (240-IL) for TGF-b and Detection kit for IL-10 (DY217-B) were purchased from R&D Systems. Concentrations of cytokines were calculated from calibration curves and expressed in pg/ml using software KIM (Schoel-ler Instruments).
Results
The original study analysed immunological characteristics of Tregs from cord blood in the context of expected risk of allergy development, based on maternal allergy status [17]. Current follow-up allowed us to correlate the data with actual allergy status of the children, an aspect critically important for considering proportion and functional characteristics of Tregs as possible predictive markers.
The proportion of Tregs, MFI of FoxP3 and intracellular presence of regulatory cytokines (IL-10 and TGF-b) were compared among the healthy and allergic children of healthy mothers and allergic mothers, respectively.
Treg ratio
When we used the gating strategy described earlier [17] and Tregs were considered as CD4+CD25highCD127lowFoxP3+, no significant difference was found between the healthy and allergic children regardless of maternal allergy status (Fig. 1A). However, when only two-colour flow cytometry analysis (CD4+CD25+) was performed, healthy children had significantly increased proportion of these cells (p = 0.0495) (Fig. 1B). Proportion of Tregs considered as CD4+FoxP3+ was not different in cord blood of healthy and allergic children, Fig. 1C).
After further dividing the two groups of children according to maternal allergy status, there was no difference in CD4+CD25highCD127lowFoxP3+ Tregs (Fig. 2A). The increase of CD4+CD25+ cells in healthy children has been driven mainly by the group of healthy children of healthy mothers (i.e., from the low-risk group; H/H), who had increased proportion of these cells compared both with allergic children of healthy mothers (A/H; p = 0.0008) and with healthy children of allergic mothers (H/A; p = 0.0418) (Fig. 2B). Notably, in the group of children of allergic mothers (i.e., the high-risk group) no trend towards lower population of CD4+CD25+ cells in allergic children is discernible, possibly hinting at a different composition or role of this population between the low-risk and high-risk groups. In addition to that, comparison of Tregs based on positivity for CD4 and FoxP3 revealed significantly increased proportion of CD4+FoxP3+ Tregs in the group of healthy children of healthy mothers in comparison to allergic children of healthy mothers (p = 0.0392) (Fig. 2C).
As the observed trends in Treg proportions were somewhat inconsistent with the original findings and other studies published previously [17, 25] and our current cohort represented a smaller subset of the subjects included in the original study, we decided to confirm whether the originally described differences between children of allergic and healthy mothers are detectable in our current data. First, we compared Treg proportions between the two groups. While difference in the proportion of CD4+CD25highCD127lowFoxP3+ does not reach statistical significance, there is a noticeable trend towards higher numbers of these cells in children of healthy mothers (p = 0.0559) (Supplementary Fig. 2A). The proportion of CD4+CD25+ subpopulation is comparable in both groups (Supplementary Fig. 2B). Similarly, no significant difference was observed between groups of children of healthy and allergic mothers in Tregs characterised as CD4+FoxP3+ cells (Supplementary Fig. 2C).
MFI of FoxP3
The original study included the MFI of FoxP3 as one of markers characterising Treg function [14, 17]. After analysing the data divided according to the child’s allergy status, we found no difference in MFI of FoxP3 between the two basic groups (healthy children versus allergic children) (Fig. 3A). Further subdivision according to the allergy status of the mother likewise revealed no difference among the groups (Fig. 3B), implying that MFI of FoxP3 may not associate with the risk of allergy development strongly enough to serve as a useful predictive factor.
Intracellular regulatory cytokines IL-10 and TGF-b
Further, we investigated whether there was lower intracellular presence of the major regulatory cytokines IL-10 and TGF-b in Treg of cord blood of children who developed allergy. No difference was found between the two basic groups for either IL-10 (Fig. 4A) or TGF-b (Fig. 4B), although a tendency toward higher values can be discerned in the healthy children. Upon further division of the samples based on the allergy status of the mothers, we uncovered significantly higher proportion of IL-10+ Tregs in cord blood of healthy children of healthy mothers (H/H) compared with both groups of high-risk children: healthy children of allergic mothers (H/A; p = 0.0146) and allergic children of allergic mothers (A/A; p = 0.0306) (Fig. 5A). Furthermore, lower proportion of TGF-b+ Tregs was observed in allergic children of allergic mothers (A/A) compared with all the other groups, i.e. allergic children of healthy mothers (A/H; p = 0.0205), healthy children of allergic mothers (H/A; p = 0.0311) and healthy children of healthy mothers (H/H; p = 0.02) (Fig. 5B). These findings are consistent with the functional importance of these cytokines in allergy and support the notion that their decreased intracellular presence is an important factor for the actual development of allergy, especially within the high-risk group of children of allergic mothers.
To see if the trends of the markers of Treg function described in the original study can be confirmed in the current smaller subgroup of subjects, we compared MFI of FoxP3 and intracellular presence of IL-10 and TGF-b in Tregs from cord blood of children of allergic mothers and children of healthy mothers, regardless of the allergy status of the children themselves. While MFI of FoxP3 did not differ between the groups (Supplementary Fig. 3A), the proportions of both IL-10+ and TGF-b+ Tregs were significantly lower in the group of children of allergic mothers, regardless of their own allergy status (p = 0.0173 and 0.0444, respectively) (Supplementary Fig. 3B and 3C, respectively), consistent with the results seen in the larger cohort [17].
Lastly, concentration of cytokines with regulatory functions (IL-10, TGF-b) was determined in cord blood sera of newborns of healthy and allergic mothers. Levels of IL-10 in cord blood sera of healthy children was not significantly increased in comparison to concentration of IL-10 in cord blood sera of children suffering from allergic diseases. There is only non-significant trend to increased values (p = 0.0681) (Fig. 6A). After division of children according to their allergy status and allergic status of their mothers, only significantly higher levels of IL-10 were observed in cord blood sera of healthy children of healthy mothers in comparison to allergic children of allergic mothers (p = 0.0422) (Fig. 6B). No difference was found in concentration of TGF-b in cord blood sera of healthy and allergic children (Fig. 6C). After subdivision of children according to both their and maternal allergy status, elevated concentration of TGF-b was found in cord blood sera of healthy children of healthy mothers in comparison to allergic children of allergy mothers (p = 0.015) and healthy children of allergic mothers (p = 0.0402) (Fig. 6D).
Discussion
It is well documented that Tregs are critically responsible for immune system regulation, evidenced by the severe autoimmune, inflammatory and allergic disorders accompanying their deficiency or dysfunction [8, 9, 28]. They play a key role in induction and maintenance of immune tolerance, from prenatal period through the infancy into adulthood [3, 29]. Numerous studies aimed to uncover whether analysis of these cells in cord blood, i.e. at the moment of birth, could be used to predict increased risk of allergy, a notion that can only be confirmed upon correlating these parameters with actual allergy development later in life [17, 21, 22, 24, 25].
In the original study, we measured proportional characteristics and parameters associated with Treg function in samples of cord blood using flow cytometry and analysed the data in the context of allergy development risk according to the allergy status of the mother [17], a commonly accepted predictive marker of increased risk of allergy development [23]. In the current follow-up, we correlated the data with clinical manifestation of allergy in childhood in a subset of the original subjects. One limitation we encountered was the low number of subjects we were able to include for the retrospective analysis – only 39 out of the 153 subjects involved in the previous study. Several factors contributed to the high drop-out rate between the original study and current follow-up. Firstly, a number of questionnaires failed to reach the subjects due to changes in the mailing address. Furthermore, a portion of recipients declined participation in the follow-up study. Finally, several respondents returned incompletely filled questionnaires which failed to provide information necessary for inclusion in analysis. This unfortunately limited the statistical power of our analyses and might account for some of the inconsistencies we observed.
While we did not see any difference in Treg proportions between healthy and allergic children when Tregs were identified as CD4+CD25highCD127lowFoxP3+ or only CD4+FoxP3+ cells, we found out that the population of CD4+CD25+ cells was increased in the healthy group. This effect was mainly due to healthy children from the low-risk group, which had higher proportion of these cells than allergic children from the low-risk group as well as healthy children from the high-risk group, with the allergic children from the high-risk group showing notably higher variance.
Although these results are supported by some published data [24, 26], they are somewhat surprising in the context of the original study, where we found that CD4+CD25+ cells were higher in the high-risk group and hypothesised that these cells might in fact be activated CD4 T cells rather than bona fide Tregs [17]. The discrepancy might be attributable to the limited number of subjects available for the retrospective study. Indeed, when the current subjects were stratified according to maternal allergy status without regard to allergy of the children, the original findings could not be confirmed, indicating that results strongly depend on selection of samples within the cohort, as well as the number of subjects analysed.
Further inconsistencies may also be due to inherent properties of Tregs and imperfect identification or understanding of the cells. Regulatory T cells represent a highly heterogeneous population, which has led to considerably diverse and sometimes contradictory reports. While some groups including ours have previously observed an increase in Tregs in cord blood of children of allergic mothers [17, 25, 30], in other studies, no difference was found [31] or even the opposite trend was reported [24, 26]. Exacerbating this are confounding factors such as differences in gating strategy and identification of Tregs [17], antibody clones used, especially in the case of FoxP3 [32]; diversity of studied cohorts, particularly considering different genetic background and environment [21, 22]; and methodical inconsistencies, including sample preparation and cohort sizes [17, 33].
Moreover, while conventional Tregs are now generally accepted to be CD4+CD25highCD127lowFoxP3+ cells in humans, numerous other subpopulations have been described in the literature. Expression of transcription factor FoxP3 is considered lineage specific for Tregs and FoxP3 MFI has been linked to suppressive function [14]. However, it has been shown that FoxP3 can be transiently induced by cell activation in non-Treg cells [34] and also that FoxP3- Treg cell populations with suppressive function both exist [35] and play a crucial role in the success of specific allergen immunotherapy [11, 35]. Currently, epigenetic analysis of demethylation of TSDR in the promotor area of foxp3 gene is proposed to better correspond to Treg phenotype stability and lineage commitment [6, 7]. Furthermore, while CD25 is the original marker first used to identify Tregs [36], it is also upregulated on activated non-Treg T cells [34], and it has been shown that CD25high (approximately the top 2% of CD25 positivity) better corresponds with bona fide Treg phenotype [37], whereas defining Tregs solely as CD4+CD25+ might include activated T cells.
Considering the diversity of Treg subpopulations, possible contamination by activated T cells and also marked plasticity of regulatory T cells [38, 39], it is interesting to note that contrary to the situation observed in the groups of low-risk children, the group of children of allergic mothers shows no tendency towards higher proportion of CD4+CD25+ cells in the healthy children. This can possibly be due to the higher variance seen among the allergic subjects from this group. It is perhaps conceivable that the ratios of particular Treg subpopulations within and/or functional significance of the observed CD4+CD25+ population might differ between the low-risk and the high-risk groups as defined by maternal allergy status, similar to how some studies report different results based on the inherent risk due to environmental factors (e.g. urban vs. farming environment [21, 22]). Utilising alternative methods of Treg characterisation (such as epigenetic analysis of TSDR) or adding more cell markers associated with Tregs into the panel (e.g. CTLA-4, PD-1, LAG3, CD39 and others [12]) in future studies to better characterise the observed populations would be necessary to conclusively confirm or deny this possibility.
In light of the abovementioned limitations and confounding factors, our findings suggest that simple analysis of proportion of Tregs might not be reliable enough to give a representative picture of perinatal immune status. Functional studies and markers associated with Treg function seem to provide better insight. While in our study there was no significant difference in MFI of FoxP3 between the healthy and allergic children, both IL-10+ and TGF-b+ Tregs have been higher in healthy children. Specifically, intracellular presence of IL-10 in Tregs was significantly higher in healthy children of healthy mothers compared with both groups of children of allergic mothers and intracellular presence of TGF-b was significantly lower in allergic children of allergic mothers than in all other groups. Taken together with the originally described increased intracellular presence of these cytokines in Tregs in cord blood of children of healthy mothers, the current results indicate that lower IL-10 and TGF-b intracellular presence in Tregs correlates with future allergy development, particularly in the high-risk group of children of allergic mothers. This observation suggests that lower levels of regulatory cytokines could be one of the promising predictive markers indicating increased risk of allergy development, which is in accordance with previously published data [19, 20].
Our findings are also consistent with the well-established role of these cytokines in immune regulation, including inducing and maintaining tolerance to environmental antigens and control of allergy [10]. IL-10 is the primary effector molecule involved in contact-independent suppression by Tregs [12] and plays an indispensable role in the success of allergen-specific immunotherapy [11, 40]. TGF-b plays a vital role in the context of mucosal immunity, including establishment and maintenance of peripheral tolerance towards microbial antigens as well as allergens [41, 42], inducing Tregs in the periphery [42] and generally tuning the mucosal immune system toward tolerogenic conditions [43, 44].
Collectively, our data support the hypothesis that evaluation of early postnatal Treg function, such as intracellular presence of regulatory cytokines, might be more useful in predicting allergy development than simple analyses of Treg population proportions, warranting further research using direct functional assays, similar to studies already published [24, 30]. It might also benefit future studies to include other markers associated with Treg function, such as surface molecules CTLA-4 or PD-1 [45-48], as some studies have already done [30]. Size of the studied cohorts is also a common limiting factor which together with high heterogeneity of allergic diseases may contribute to the inconsistencies reported in literature [17, 33]. Furthermore, reliable identification of stable Treg phenotype using novel techniques, chiefly epigenetic analysis of TSDR demethylation status, might shed some light into the conflicting reports regarding population proportions of Tregs and their relevance between different subject groups at higher/lower risk of allergy development. Of course, the final verdict regarding the real benefit of the proposed approaches for early prediction of allergy will only be possible upon correlating the data measured at the time of birth with the actual development of allergy later in life. So far, while there is a multitude of studies which characterise Treg populations and functional parameters in cord blood, relatively few studies correlate their findings with clinical data obtained later during life [24].